Literature DB >> 26144937

Disruption of Circadian Rhythms and Sleep in Critical Illness and its Impact on the Development of Delirium.

Benjamin K Scott1.   

Abstract

PURPOSE: This article reviews our current understanding of the relationships between critical illness, circadian disruption, and delirium.
SUMMARY: Delirium is a common and morbid complication of hospitalization, particularly in the setting of critical illness and intensive care unit (ICU) admission. Critical illness involves a host of acute metabolic, hormonal and inflammatory responses that appear to disrupt normal sleep architecture and precipitate cerebral dysfunction. The intervention-heavy environment of the ICU further disrupts normal circadian rhythms and increases delirium risk. Despite strong evidence for correlation of sleep disruption, critical illness and delirium, causal relationships remain difficult to prove. Delirium is almost certainly a multifactorial condition. This article reviews proposed pathophysiologic mechanisms and potential therapeutic targets. In the absence of definitive pharmacologic therapy, interventions prioritizing maintenance of normal circadian, sleep, and behavioral patterns have shown promise in delirium risk reduction.

Entities:  

Mesh:

Year:  2015        PMID: 26144937     DOI: 10.2174/1381612821666150706110656

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  12 in total

1.  The impact of sedation protocols on outcomes in critical illness.

Authors:  Benjamin Scott; Tobias Eckle
Journal:  Ann Transl Med       Date:  2016-01

2.  Early Postoperative Actigraphy Poorly Predicts Hypoactive Delirium.

Authors:  Hannah R Maybrier; C Rya King; Amanda E Crawford; Angela M Mickle; Daniel A Emmert; Troy S Wildes; Michael S Avidan; Ben Julian A Palanca
Journal:  J Clin Sleep Med       Date:  2019-01-15       Impact factor: 4.062

3.  Editorial: Health Impact and Management of a Disrupted Circadian Rhythm and Sleep in Critical Illnesses.

Authors:  Tobias Eckle
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

4.  Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis.

Authors:  Yi-Cheng Wu; Ping-Tao Tseng; Yu-Kang Tu; Chung-Yao Hsu; Chih-Sung Liang; Ta-Chuan Yeh; Tien-Yu Chen; Che-Sheng Chu; Yutaka J Matsuoka; Brendon Stubbs; Andre F Carvalho; Saho Wada; Pao-Yen Lin; Yen-Wen Chen; Kuan-Pin Su
Journal:  JAMA Psychiatry       Date:  2019-05-01       Impact factor: 21.596

5.  A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction.

Authors:  Jennifer Gile; Yoshimasa Oyama; Sydney Shuff; Tobias Eckle
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

6.  The Period 2 Enhancer Nobiletin as Novel Therapy in Murine Models of Circadian Disruption Resembling Delirium.

Authors:  Jennifer Gile; Benjamin Scott; Tobias Eckle
Journal:  Crit Care Med       Date:  2018-06       Impact factor: 7.598

Review 7.  The significance of circadian rhythms and dysrhythmias in critical illness.

Authors:  Helen T McKenna; Irwin Km Reiss; Daniel S Martin
Journal:  J Intensive Care Soc       Date:  2017-02-13

8.  The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion Injury.

Authors:  Yoshimasa Oyama; Colleen Marie Bartman; Jennifer Gile; Daniel Sehrt; Tobias Eckle
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

Review 9.  Behavioral, Psychiatric, and Cognitive Adverse Events in Older Persons Treated with Glucocorticoids.

Authors:  Ciro Manzo; Jordi Serra-Mestres; Alberto Castagna; Marco Isetta
Journal:  Medicines (Basel)       Date:  2018-08-01

10.  Intelligent ICU for Autonomous Patient Monitoring Using Pervasive Sensing and Deep Learning.

Authors:  Anis Davoudi; Kumar Rohit Malhotra; Benjamin Shickel; Scott Siegel; Seth Williams; Matthew Ruppert; Emel Bihorac; Tezcan Ozrazgat-Baslanti; Patrick J Tighe; Azra Bihorac; Parisa Rashidi
Journal:  Sci Rep       Date:  2019-05-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.